SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending amid discussions around its Q3 earnings, which beat expectations, and updated guidance. The community is focused on the company's high valuation, with some citing Michael Burry's reported short position, while others remain bullish due to Palantir's growth and position in AI.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

SMCI is trending as investors weigh the impact of AI infrastructure spending by major tech companies against concerns about SMCI's recent performance and upcoming earnings. The community is closely watching for any news or updates on partnerships, particularly with Xai, and whether the company can maintain its revenue guidance. Discussions also involve the potential for a new CFO announcement and its impact on investor confidence.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending due to recent trial results for its PMO therapies, which, while showing positive trends, did not meet statistical significance, leading to community concerns about potential revenue impact. Despite this, discussions focus on the potential for label expansion of Elevidys, European sales, and possible mergers or acquisitions as long-term catalysts. Some traders also suggest shorts may have orchestrated the selloff.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta (META) is trending amid investor concern over heavy AI spending and its potential impact on near-term profitability, leading to a sell-off from recent highs. Community discussions revolve around identifying a bottom and whether the stock is oversold, with some viewing the dip as a buying opportunity due to Meta's strong fundamentals and long-term potential in AI and VR.

Baidu, Inc. engages in the provision of internet search and online marketing solutions. The firm’s products and services include Baidu App, Baidu Search, Baidu Feed, Haokan, Quanmin, Baidu Post Bar, Baidu Knows, Baidu Encyclopedia, Baidu Input Method Editor or Baidu IME, Baidu AI Cloud and Overseas Products. It operates through the following segments: Baidu Core and iQIYI. The Baidu Core segment provides search-based, feed-based, and other online marketing services. The iQiyi segment is an online entertainment service provider, which offers original, professionally produced and partner-generated content on its platform. The company was founded by Yanhong Li and Xu Yong on January 18, 2000 and is headquartered in Beijing, China.

Baidu Inc - ADR

Baidu is trending as its robotaxi fleet, Apollo Go, matches Waymo's pace with weekly ride volumes crossing 250K, sparking excitement around its autonomous vehicle leadership. Community members are also discussing catalysts from upcoming earnings and AI advancements, with some eyeing price targets. The stock's multi-year accumulation and perceived undervaluation as a Chinese stock are also driving interest.

Energy Fuels, Inc. is a mining development company, which engages in the exploration and evaluation of uranium and vanadium properties. It also operates the Nichols Ranch, Alta Mesa, and White Mesa Mill projects. The company was founded by George E. L. Glasier and John David Mason on June 24, 1987 and is headquartered in Lakewood, CO.

Energy Fuels Inc

Energy Fuels is trending due to a mixed reaction to earnings, with revenue doubling but EPS missing estimates, sparking debate about valuation and future guidance. Community members are discussing the potential for a short squeeze and government contracts, while also weighing the impact of a possible easing of rare earth export restrictions by China. Bullish sentiment remains strong among some investors who view Energy Fuels as a key player in the uranium and rare earth sectors, essential for energy independence and AI infrastructure.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

The "crow with knife" meme coin, $CAW, is gaining attention, with community members emphasizing its multichain presence across $SOL, $ETH, $CRO, and BASE. Discussions highlight its fully circulated supply, deflationary mechanisms, strong community, and organic growth. The community is actively using the catchphrase "caw caw" and mentioning partnerships.

Grab Holdings Ltd. engages in the provision of millions of people each day to access its driver- and merchant-partners to order food or groceries, send packages, hail a ride or taxi, pay for online purchases or access services such as lending, insurance, wealth management and telemedicine, all through a single “everyday everything” app. The firm operates in food deliveries and mobility and by TPV in the e-wallets segment of financial services in Southeast Asia. It operates across the deliveries, mobility and digital financial services sectors in eight countries namely: Cambodia, Indonesia, Malaysia, Myanmar, the Philippines, Singapore, Thailand and Vietnam. The company was founded by Anthony Tan Ping Yeow and Tan Hooi Ling in 2012 and is headquartered in Singapore.

Grab Holdings Limited - Ordinary Shares - Class A

Grab Holdings Limited

GRAB is trending as investors discuss its potential, fueled by high trading volume and a breakout from a multi-year base. Community members are analyzing call option activity and speculating on price targets, while highlighting its strong presence in Southeast Asia. Some are also noting positive developments such as partnerships and institutional accumulation, though a recent analyst downgrade has tempered sentiment for some.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as investors await Phase 3 data for its DMD treatment, with community discussions focusing on the potential impact of results given recent FDA activity and competitor setbacks. Talking points include the company's financial position, potential milestones, and the StealthX exosome platform. Anticipation is building, with some suggesting a significant market shift is on the horizon pending the data readout.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

HIMS is trending amid discussions about its upcoming earnings report and a potential partnership with Novo Nordisk, which has sparked debate around the company's GLP-1 strategy. Community members are weighing the potential impact of these factors on the stock's future performance, with some anticipating a short squeeze. Others are focused on insider selling and revenue guidance, remaining skeptical about the company's valuation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

TG Therapeutics, Inc. (TGTX) on Monday raised the full-year revenue guidance for its multiple sclerosis drug, Briumvi, to reflect strong market demand.The company now <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-reports-third-quarter-2025-financial-results-and">expects</a> full-year Briumvi U.S. net revenue to be approximately $585 million, up from its previous guidance of $570 million to $575 million. The company also subsequently raised its full-year overall revenue guidance to $600 million, up from its previous forecast of $585 million.<h2 class="st-heading-2">TG’s Blockbuster Drug</h2>Briumvi is a prescription medication used to treat adults with relapsing forms of multiple sclerosis (MS). Multiple sclerosis (MS) is an autoimmune disease where the immune system attacks the myelin sheath, the protective covering of nerve cells in the brain and spinal cord. This damage disrupts nerve signals, leading to a wide range of neurological symptoms, including numbness, vision problems, and difficulties with balance, coordination, and walking.“As we move through the fourth quarter, we remain focused on expanding patient awareness, advancing enrollment into our ongoing clinical trials, and driving growth and long-term value for our shareholders,” CEO Michael S. Weiss said on Monday.The company is currently undertaking two late-stage programs of Briumvi, evaluating subcutaneous and intravenous formulations of the drug.In the third quarter, the company reported total revenue of $161.7 million, of which Briumvi U.S. revenue accounted for about 95%. This also beat an analyst estimate of $152.17 million, according to data from Fiscal AI.Net income for the quarter came at $390.9 million, compared to $3.9 million in the corresponding quarter of 2024. The company ended the quarter with cash, cash equivalents, and investment securities of $178.3 million, which it expects to be sufficient to fund its business, when coupled with Briumvi revenues.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2><a href="https://stocktwits.com/symbol/TGTX">Shares of TGTX</a> jumped 4% in the premarket session at the time of writing. On Stocktwits, retail sentiment around TGTX stayed within the ‘bullish’ territory over the past 24 hours, while message volume stayed within ‘high’ levels.TGTX stock is up 16% this year and approximately 43% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/pfizer-files-second-lawsuit-against-metsera-novo-nordisk/cL2N3Z5R3zi">The Battle For Metsera Acquisition Heats Up As Pfizer Files A Second Lawsuit</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

TG Therapeutics Stock Soars After Company Ups Guidance For Multiple Sclerosis Drug

The company now expects full-year Briumvi U.S. net revenue to be approximately $585 million, up from its previous guidance of $570 million to $575 million.

Equity

The company now expects full-year Briumvi U.S. net revenue to be approximately $585 million, up from its previous guidance of $570 million to $575 million.


Arcus Biosciences, Inc. (RCUS) Reports Q3 Loss, Beats Revenue Estimates

Arcus Biosciences (RCUS) delivered earnings and revenue surprises of +4.51% and +27.20%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Amgen (AMGN) Q3 Earnings Expected to Decline

Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

TG Therapeutics (TGTX) Earnings Expected to Grow: What to Know Ahead of Q3 Release

TG Therapeutics (TGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Strength Seen in uniQure (QURE): Can Its 247.7% Jump Turn into More Strength?

uniQure (QURE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Why Is TG Therapeutics (TGTX) Up 4.7% Since Last Earnings Report?

TG Therapeutics (TGTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

TG Therapeutics, Inc. (TGTX) on Wednesday stated that its board of directors has authorized a new share repurchase program to acquire up to an additional $100 million of the company’s common stock.The new share repurchase authorization follows the company's completion of its previously authorized $100 million share repurchase program, initially announced in August 2024. Under the previous program, TG Therapeutics repurchased a total of approximately 3.5 million shares of its common stock at an average price of $28.55 per share. CEO Michael S. Weiss <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-announces-completion-existing-share-repurchase">said</a> that the company repurchased $78 million of the stock in August alone at “highly attractive prices.”TGTX stock gained nearly 2% in Wednesday’s pre-market.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/TGTX">TGTX stock</a> stayed within ‘bearish’ territory over the past 24 hours, while message volume rose from ‘extremely low’ to ‘low’ levels.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-announces-completion-existing-share-repurchase">said</a> on Wednesday that repurchases under the new program may be made on a time-to-time basis through open market purchases, privately negotiated transactions, or other means.Weiss said that the new repurchase program reflects the company’s conviction that “current market prices do not adequately reflect the multibillion-dollar potential of Briumvi or the long-term growth prospects of TG Therapeutics.”Briumvi is a medication used to treat relapsing forms of multiple sclerosis (MS) in adults. Multiple Sclerosis is a chronic, often disabling, autoimmune disease that affects the brain and spinal cord, disrupting communication between the brain and other parts of the body. The disease symptoms include difficulty walking, blurred vision, and altered sensations in limbs or face.In the <a href="https://stocktwits.com/news-articles/markets/equity/tg-therapeutics-stock-tumbles-after-disappointing-q2-but-company-reaffirms-confidence-in-multiple-sclerosis-drug/chrXrTDRdcR">second quarter</a>, Briumvi’s net product revenue totaled $138.8 million, representing 91% growth over the same period last year and accounting for over 98% of the company’s total revenue.TGTX stock is down 1% this year but up approximately 31% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tectonic-stock-soars-pre-market-after-tuesday-sell-off/chwTUeNRd8m">Tectonic Stock Soars Pre-market After Tuesday’s Sell-Off: Oppenheimer Is Hopeful About Company’s Lead Candidate</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 TG Therapeutics Board Authorizes New $100M Share Repurchase Program

The new share repurchase authorization follows the company's completion of its previously authorized $100 million share repurchase program, initially announced in August 2024.

TGTX Down as Q2 Earnings Miss Mark, Briumvi Sales Drive Top Line

TG Therapeutics slides 18% as second-quarter earnings fall short despite a 92% revenue jump fueled by surging Briumvi sales.

 Company News for Aug 5, 2025

TG Therapeutics, Inc. (TGTX) on Monday reaffirmed confidence in its flagship drug Briumvi despite a disappointing second-quarter earnings report.Briumvi is a medication used to treat relapsing forms of multiple sclerosis (MS) in adults. Multiple Sclerosis is a chronic, often disabling, autoimmune disease that affects the brain and spinal cord, disrupting communication between the brain and other parts of the body. The disease symptoms include difficulty walking, blurred vision, and altered sensations in limbs or face.“With multiple growth drivers in place, expanding patient and prescriber bases, increasing brand recognition and the momentum of our media investments, we believe Briumvi is on track to become a multibillion-dollar brand in relapsing MS,” said Adam Waldman, Chief Commercial Officer at TG Therapeutics, on the company’s earnings call while adding that it expects stronger growth from the third quarter (Q3) to the fourth quarter (Q4).The firm also raised its Briumvi U.S. net product revenue target to $570 million to $575 million for the full year 2025, up from its previous guidance of $560 million. TG Therapeutics is also evaluating Briumvi in the treatment of Myasthenia Gravis and testing subcutaneous Briumvi, allowing self-administration of the drug.The company now sees a total global revenue target of approximately $585 million for the full year 2025, up from its previous guidance of $575 million.&nbsp;On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/TGTX">TGTX</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours while message volume rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:1336/132;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_04_at_1_21_31_PM_png_bda23ffe5e.webp" alt="TGTX's Sentiment Meter and Message Volume as of 1:20 p.m. ET on Aug. 4, 2025 | Source: Stocktwits" width="1336" height="132"><figcaption>TGTX's Sentiment Meter and Message Volume as of 1:20 p.m. ET on Aug. 4, 2025 | Source: Stocktwits</figcaption></figure>TGTX stock slid over 16% on Monday following the downbeat earnings. A Stocktwits user believes the drop in stock following the earnings report is an opportunity to buy more.<stembedurl>https://stocktwits.com/Firstcall/message/623650797</stembedurl>Another opined that the drop is not justifiable, given that the company raised its guidance.<stembedurl>https://stocktwits.com/Firstcall/message/623647493</stembedurl>For the second quarter, the company’s total revenue came in at $141.15 million, compared to $73.47 million in the corresponding quarter of 2024, and below an analyst estimate of $147.76 million. Briumvi’s net product revenue alone came in at $138.8 million, representing 91% growth over the same period last year, and accounting for over 98% of the company’s total revenue.Diluted earnings per share came in at $0.17, above the $0.04 reported in Q2 2024, but below an analyst estimate of $0.25.&nbsp;TGTX stock is down by 3% this year but up by 70% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/lucid-rivian-to-report-q2-earnings-tomorrow/chrXpf7RdTz">Lucid, Rivian To Report Q2 Earnings Tomorrow: Retail Watches Warily With Mixed Sentiments</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

TG Therapeutics Stock Tumbles 16% After Disappointing Q2, But Company Reaffirms Confidence In Multiple Sclerosis Drug

The company raised its Briumvi U.S. net product revenue target to $570 million to $575 million for the full year 2025, up from its previous guidance of $560 million.

TG Therapeutics Stock Tumbles 15% After Disappointing Q2, But Company Reaffirms Confidence In Multiple Sclerosis Drug

The company raised its Briumvi U.S. net product revenue target to $570 million to $575 million for the full year 2025, up from its previous guidance of $560 million.


$TGTX Q3 &#39;25 Earnings Results &amp; Recap 
 
TG Therapeutics reported Q3 revenue of $161.7M, beating estimates of $152.11M, and EPS of $2.43, which includes a one-time, non-recurring $365 million tax benefit; adjusted EPS is closer to $0.20, with full year revenue guidance raised to $585M.

Stocktwits

TG Therapeutics Inc

 Q3 '25 Earnings Results & Recap 
 
TG Therapeutics reported Q3 revenue of $161.7M, beating estimates of $152.11M, and EPS of $2.43, which includes a one-time, non-recurring $365 million tax benefit; adjusted EPS is closer to $0.20, with full year revenue guidance raised to $585M.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

Will Robinhood Markets ($HOOD) beat quarterly earnings? 
 
*Powered by Polymarket

Robinhood Markets Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$32.57
Prev Close	$34.78
Open	$36.30
Dividend Yield	0.00%
50-Day Moving Average	$33.53
Beta	1.53
Avg. Volume	1.62M
PE Ratio	90.03

52-Week High	$46.48
52-Week Low	$23.60
Market Capitalization	$5.35B
EPS (Annual)	$0.1458
Price to Book	19.26
Revenue Per Employee	$973,384.61
Enterprise Value/EBITDA	N/A

TGTX
TG Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TGTX News

TGTXTG Therapeutics Inc